Gene:
PRTN3
proteinase 3

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB contains no drug labels with pharmacogenomic information for this . To report a drug label with PGx, click here.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

This is a non-comprehensive list of genetic tests with pharmacogenetics relevance, typically submitted by the manufacturer and manually curated by PharmGKB. The information listed is provided for educational purposes only and does not constitute an endorsement of any listed test or manufacturer.

A more complete listing of genetic tests is found at the Genetic Testing Registry (GTR).

PGx Test Variants Assayed Related Drugs?

Overview

Alternate Names:  Wegener granulomatosis autoantigen; myeloblastin; serine proteinase, neutrophil
Alternate Symbols:  ACPA; AGP7; C-ANCA; MBT; P29; PR-3
PharmGKB Accession Id: PA33842

Details

Cytogenetic Location: chr19 : p13.3 - p13.3
GP mRNA Boundary: chr19 : 840985 - 848175
GP Gene Boundary: chr19 : 830985 - 851175
Strand: plus
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.

LinkOuts

Entrez Gene:
5657
OMIM:
177020
UCSC Genome Browser:
NM_002777
RefSeq RNA:
NM_002777
RefSeq Protein:
NP_002768
RefSeq DNA:
AC_000062
AC_000151
NC_000019
NT_011255
NW_001838476
NW_927173
UniProtKB:
PRTN3_HUMAN (P24158)
Ensembl:
ENSG00000196415
GenAtlas:
PRTN3
GeneCard:
PRTN3
MutDB:
PRTN3
ALFRED:
LO177319C
HuGE:
PRTN3
Comparative Toxicogenomics Database:
5657
ModBase:
P24158
HumanCyc Gene:
HS10473
HGNC:
9495

Common Searches